Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On May 27, 2025, the voluntary petition of Biora Therapeutics, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on December 27, 2024.
Часто задаваемые вопросы
В каком секторе работает BIORQ (BIORQ)?
BIORQ относится к сектору Прочее.
Какова текущая цена акций BIORQ (BIORQ)?
По последним данным, цена акций BIORQ составляет 0,00 $, предыдущее закрытие — 0,00 $.
Выплачивает ли BIORQ (BIORQ) дивиденды?
Нет, BIORQ не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у BIORQ (BIORQ)?
У компании BIORQ бета 159.564, что свидетельствует о крайне высокой волатильности по сравнению с рынком
